C2 PHARMA Marks 10th Year Anniversary Attendance at CPhI Milan with Expanded Ophthalmic API Portfolio

Cork, Ireland, September 24^th, 2024 –  C² PHARMA, the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), recently celebrated its 10th year as a company and will also be celebrating its decade-long attendance at CPhI worldwide. The company recently launched Naphazoline Hydrochloride, expanding its ophthalmic API portfolio, while it also received approval for a Certificate of Suitability (CEP) for Tropicamide.

“Our global leadership in ophthalmic APIs is underpinned by our willingness to set the bar higher at all levels,” states Andrew Badrot, CEO of C² PHARMA. “ We are committed to providing our customers APIs with unparalleled cost-to-quality, cost-to-reliability, and always stay focused on how to improve their speed-to-market. Through excellence and hard work, we ensure that our clients receive the best value for money, maintaining our position at the forefront of the API industry.”

C² PHARMA’s portfolio expansion will continue into the upcoming 24-month year and include the following product launches:

• Naphazoline Nitrate
• Timolol Maleate
• Dorzolamide Hydrochloride
• Brinzolamide and Brinzolamide (sterile)
• Oxybuprocaine Hydrochloride
• Indocyanine Green

C² PHARMA’s regulatory filings under submission include:

 Atropine Sulfate

• CADIFA

Homatropine Methylbromide

• CADIFA

Naphazoline Hydrochloride

• CEP
• US-DMF
• CADIFA

Brimonidine Tartrate

• C-DMF
• CADIFA

Latanoprost

• CEP

Tropicamide

• C-DMF
• J-DMF

A full list of C² PHARMA’s products and filings can be found here, with the R&D pipeline available here.

The company will exhibit at CPhI Worldwide 2024 in Milan from October 8th to 10th  in Hall 4, Booth A11, with its affiliate, Logisitics4Pharma. To schedule a meeting, please email info@c2pharma.com.